minor changes

Author: ypriverol

sdrf-proteomics/templates/human/README.adoc

@@ -475,6 +475,7 @@ For longitudinal studies, indicates when sample was collected relative to a refe
 
 Values: `baseline`, `week 1`, `day 7`, `post-treatment`, `follow-up`.
 
+[[clinical-specific-terms]]
 == Clinical-Specific Terms
 
 This section describes columns for capturing clinical metadata in human studies, applicable to patient samples regardless of disease type.
@@ -514,7 +515,7 @@ Comorbidities or pre-existing medical conditions. For multiple conditions, use m
 
 |High blood pressure |hypertension |MONDO:0005044
 |Diabetes |type 2 diabetes mellitus |MONDO:0005148
-|Heart disease |coronary artery disease |MONDO:0004975
+|Heart disease |coronary artery disease |MONDO:0005010
 |Obesity |obesity |MONDO:0011122
 |===
 
@@ -644,6 +645,7 @@ endif::[]
 
 Captures relevant medical history information for the patient.
 
+[[cancer-specific-terms]]
 == Cancer-Specific Terms
 
 This section describes columns specific to cancer proteomics studies. These terms are distinct from general clinical staging and provide detailed tumor characterization.
@@ -958,6 +960,7 @@ Number of mitoses per high-power field. Used for histological grading in some ca
 * `characteristics[Gleason score]` - Prostate cancer grading
 * `characteristics[Weiss grade]` - Adrenal cortical carcinoma (low, high)
 
+[[sampling-site]]
 == Sampling Site
 
 ifdef::backend-html5[]
@@ -1075,6 +1078,7 @@ characteristics[sampling site]: tumor
 3. **Do NOT use multiple organism part columns** - This pattern is not recommended
 4. Use lowercase for all values
 
+[[phenotype-and-biomarkers]]
 == Phenotype and Biomarkers
 
 For general phenotype annotation guidelines applicable to all organisms, see link:sample-metadata.adoc#phenotype-annotation[Sample Metadata Guidelines - Phenotype].
@@ -1189,6 +1193,7 @@ characteristics[genotype]: TP53 R175H
 |Drug sensitivity |`characteristics[phenotype]` |cisplatin resistant |Functional drug response
 |===
 
+[[treatment-and-perturbation-metadata]]
 == Treatment and Perturbation Metadata
 
 This section describes columns for capturing drug treatment, compound exposure, and perturbation information. These fields are critical for pharmacoproteomics studies and treatment comparison experiments.

site/index.html

@@ -149,14 +149,14 @@ <h3>Experiment-specific Templates</h3>
                         <tr>
                             <td><a href="./templates/affinity-proteomics.html">Affinity Proteomics</a></td>
                             <td>Olink, SomaScan, Luminex, and other affinity-based methods</td>
-                            <td><span class="status-dev">Under Development</span></td>
-                            <td>1.1.0-dev</td>
+                            <td><span class="status-released">Released</span></td>
+                            <td>1.0.0</td>
                         </tr>
                         <tr>
                             <td><a href="./templates/crosslinking.html">Crosslinking</a></td>
                             <td>XL-MS structural proteomics experiments</td>
-                            <td><span class="status-dev">Under Development</span></td>
-                            <td>1.1.0-dev</td>
+                            <td><span class="status-released">Released</span></td>
+                            <td>1.0.0</td>
                         </tr>
                         <tr>
                             <td><a href="./templates/immunopeptidomics.html">Immunopeptidomics</a></td>